Noramco Buprenorphine Hydrochloride Noramco Buprenorphine Hydrochloride

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Orexo","sponsor":"Accord healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV\u00ae in Europe","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orexo Announces New Us Patent for Zubsolv\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NIH Supported Study Shows Emergency Department-Administered, High-Dose Buprenorphine May Enhance Opioid Use Disorder Treatment Outcomes","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"MMCAP Infuse","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Purdue Pharma L.P. Enters Agreement to Provide Low-cost Opioid use Disorder Treatment to Correctional Facilities for Incarcerated Individuals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

    Menu

    BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Purdue Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Purdue Pharma L.P. Enters Agreement to Provide Low-cost Opioid use Disorder Treatment to Correctional Facilities for Incarcerated Individuals

              Details:

              The agreement aims to provide buprenorphine and naloxone tablets CIII (generic Suboxone), a medication for opioid use disorder, at low cost to correctional facilities for incarcerated individuals with opioid use disorder.

              Lead Product(s): Buprenorphine Hydrochloride,Naloxone Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: Suboxone-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: MMCAP Infuse

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 06, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              National Institutes of Health

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NIH Supported Study Shows Emergency Department-Administered, High-Dose Buprenorphine May Enhance Opioid Use Disorder Treatment Outcomes

              Details:

              The data analysis showed that in 63% of cases, the clinicians administered more than the standard upper limit of 12 mg of sublingual buprenorphine during emergency department induction, and in 23% of cases, patients were given 28 mg or more.

              Lead Product(s): Buprenorphine Hydrochloride,Naloxone Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: Zubsolv

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orexo

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orexo Announces New Us Patent for Zubsolv®

              Details:

              The new patent, US Patent further strengthens the company's intellectual property for ZUBSOLV® in the US. Orexo will now have six patents listed in the Orange Book for ZUBSOLV®.

              Lead Product(s): Buprenorphine Hydrochloride,Naloxone Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: Zubsolv

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orexo

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orexo Enters Exclusive License and Supply Agreement with Accord Healthcare for ZUBSOLV® in Europe

              Details:

              Under the terms of the agreement, Orexo will be responsible for product supply and Accord will take responsibility for the commercialisation of ZUBSOLV®. Orexo will receive double-digit royalties on future net sales.

              Lead Product(s): Buprenorphine Hydrochloride,Naloxone Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: Zubsolv

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Accord healthcare

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement December 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Temad Buprenorphine Hydrochloride
              Pluviaendo Buprenorphine HCl
              Close
              4
              Post Enquiry
              POST ENQUIRY